Who are Pluvicto's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gallium Oxydatum, MDV3100, Pluvicto, Pluvicto, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lutetium-177lu-vipivotide-tetraxetan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Pluvicto — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pluvicto (Lutetium (177Lu) vipivotide tetraxetan) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radioligand Therapeutic Agent [EPC]. Area: Oncology.

marketed Radioligand Therapeutic Agent [EPC] Prostate-specific antigen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pluvicto (Lutetium (177Lu) vipivotide tetraxetan) — Aaa Usa Novartis. Pluvicto works by binding to prostate-specific antigen (PSMA) on cancer cells, delivering a radioactive payload that kills the cells.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pluvicto TARGET	Lutetium (177Lu) vipivotide tetraxetan	Aaa Usa Novartis	marketed	Radioligand Therapeutic Agent [EPC]	Prostate-specific antigen	2022-01-01
Gallium Oxydatum	GALLIUM	Novartis	marketed		Glutamate carboxypeptidase 2, Prostate-specific antigen	2025-01-01
MDV3100	mdv3100	Pfizer Inc.	marketed	Androgen receptor inhibitor	Androgen receptor, Glucocorticoid receptor, Prostate-specific antigen
Pluvicto	Pluvicto	VA Office of Research and Development	marketed		Prostate-specific antigen
Pluvicto	TETRAXETAN	Novartis	marketed	Radioligand Therapeutic Agent [EPC]		2025-01-01
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN	LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN		marketed	Radioligand Therapeutic Agent [EPC]	PSMA	2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-08-15 — Pluvicto · 10406240 · US
2028-08-15 — Pluvicto · 11318121 · US
2034-10-17 — Pluvicto · 10398791 · US

Sponsor landscape (Radioligand Therapeutic Agent [EPC] class)

· 1 drug in this class
Aaa Usa Novartis · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pluvicto — Competitive Intelligence Brief. https://druglandscape.com/ci/lutetium-177lu-vipivotide-tetraxetan. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab